Answers are grounded in this paper and cite their sources.
Prostate-specific antigen (PSA) kinetics during neoadjuvant hormonal therapy (NHT) may provide prognostic information for patients undergoing radical prostatectomy (RP), but previous studies have relied on single summary parameters. This study aimed to identify PSA trajectory classes during NHT using latent class growth mixture modeling (LCGMM) and to evaluate their association with postoperative event-free survival (EFS). This single-center retrospective study included 166 patients with prostate cancer who received NHT followed by RP between January 2021 and December 2024. Serial PSA measurements during NHT were analyzed using LCGMM. EFS was defined as the time from RP to biochemical recurrence, local or regional recurrence, distant metastasis, or death. Cox models were adjusted for initial PSA, clinical T stage, ISUP Grade Group, clinical M stage and adjuvant hormonal therapy. Sensitivity analyses addressed disease extent, adjuvant therapy, postoperative PSA persistence and classification uncertainty; internal validation used bootstrapping. Three trajectory classes were identified: slow decline with rebound (33.7%), intermediate sustained decline (44.6%) and rapid-deep decline (21.7%). At a median follow-up of 22.0 months, 2-year EFS rates were 54% (95% CI 38–67%), 80% (68–88%) and 90% (73–97%), respectively (log-rank P = 0.0017). In multivariable analysis, the rapid-deep decline class was associated with a lower risk of events than the slow decline with rebound class (HR 0.16; 95% CI 0.06–0.43; P < 0.001), whereas the intermediate sustained decline class did not differ significantly (HR 0.59; 95% CI 0.31–1.12; P = 0.107). Adding trajectory class improved model fit (likelihood ratio χ² = 17.38, df = 2, P = 0.0002; optimism-corrected C-index 0.741 vs. 0.677). The association for the rapid-deep decline class persisted in cN0M0 patients (HR 0.11; 95% CI 0.03–0.40), after exclusion of patients with postoperative PSA persistence (HR 0.18; 95% CI 0.06–0.49) and in patients without adjuvant hormonal therapy (adjusted HR 0.06; 95% CI 0.01–0.56). In this retrospective cohort, PSA trajectory classes during NHT were associated with EFS after RP, mainly reflecting the favorable outcome of patients with a rapid-deep PSA decline. These hypothesis-generating findings require external validation in larger cohorts with longer follow-up before PSA trajectories can be used for risk stratification.
No takes yet. Share an insight, caveat, or question.
Dai et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: